Coya Therapeutics, Inc. SEC filings COYA
Coya Therapeutics, Inc. has 230 filings in SEC EDGAR's recent list, going back to Jan 5, 2021. Its latest annual report, Form ARS, was filed on May 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Aug 7, 2026 | Mar 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Material agreement
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 2, 2026 | Mar 29, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 16, 2026 | Mar 16, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Jan 30, 2026 | Jan 29, 2026 |
| 8-K |
Current report
Other events
|
Jan 20, 2026 | Jan 20, 2026 |
| 8-K |
Current report
Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Other events
|
Dec 17, 2025 | Dec 16, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 27, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Other events
|
Sep 2, 2025 | Aug 29, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Other events
|
Jul 29, 2025 | Jul 29, 2025 |
| 8-K |
Current report
Other events
|
Jul 1, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 26, 2025 | Jun 26, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 18, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 6, 2024 | Nov 6, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 5, 2024 | Nov 1, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 31, 2024 | Oct 28, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2024 | Oct 29, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Oct 22, 2024 | Oct 21, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 19, 2024 | Aug 16, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2024 | Aug 12, 2024 |
| 8-K |
Current report
Other events
|
Jul 15, 2024 | Jul 12, 2024 |
| 8-K |
Current report
Material agreement
|
Jun 5, 2024 | Jun 4, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 20, 2024 | May 17, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 8, 2024 | May 8, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 19, 2024 | Mar 19, 2024 |
| 8-K |
Current report
Other events
|
Jan 19, 2024 | Jan 19, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 20, 2023 | Dec 19, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Dec 6, 2023 | Dec 5, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 8, 2023 | Nov 8, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 21, 2023 | Aug 18, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Officer or director change
|
Jul 14, 2023 | Jul 11, 2023 |
| 8-K |
Current report
Officer or director change
|
Jul 10, 2023 | Jul 3, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2023 | Jun 28, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 12, 2023 | Jun 12, 2023 |
| 8-K |
Current report
Other events
|
May 23, 2023 | May 22, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 16, 2023 | May 16, 2023 |
| 8-K |
Current report
Results of operations
|
May 10, 2023 | May 10, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2023 | Mar 29, 2023 |
| 8-K |
Current report
Material agreement
|
Mar 22, 2023 | Mar 16, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 21, 2023 | Mar 21, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 13, 2023 | Mar 13, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 1, 2023 | Feb 27, 2023 |
| 8-K |
Current report
Other events
|
Jan 25, 2023 | Jan 25, 2023 |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.